Palatin Technologies reported a net loss of $5.4 million for the third quarter of fiscal year 2020, compared to a net loss of $5.7 million for the same period in 2019. The company's cash and cash equivalents were $88.9 million as of March 31, 2020. They are continuing to advance their clinical programs.
Net loss was $(5.4) million, compared to $(5.7) million for the comparable quarter of 2019.
Operating expenses were $5.7 million, compared to $5.8 million for the comparable quarter of 2019.
Other income was $331,007, compared to $35,648 for the comparable quarter of 2019.
Cash and cash equivalents were $88.9 million as of March 31, 2020, compared to $91.5 million as of December 31, 2019.
Management believes that existing capital resources will be adequate to fund the Company’s planned operations through at least March 31, 2022.